Soleno Therapeutics (SLNO) Q4 2025 earnings review
Stunning Profitability Reverses Cash Burn, But Leading Indicators Flash Red
Soleno Therapeutics capped off its first commercial year with an exceptional financial performance. VYKAT XR revenue accelerated sequentially to $91.7M in Q4, driving $43.4M in net income and $48.7M in operating cash flow. The company has successfully transitioned from a clinical-stage cash burner to a highly profitable commercial entity in just three quarters. However, behind the pristine income statement lies a severe deceleration in leading indicators. Patient start forms plummeted from 646 in Q2 to just 207 in Q4, contradicting management's claim of a 'positive trajectory.' While the financial momentum is incredibly strong today, the diminishing pipeline of new patients poses a significant risk to revenue growth in FY26.
🐂 Bull Case
The company generated a remarkable $43.4M in net income (47% net margin) and $48.7M in operating cash flow in Q4 alone. VYKAT XR's near-100% gross margin and controlled SG&A expansion are creating a cash-printing machine.
Covered lives accelerated from 132M in Q3 to 185M in Q4, representing over 60% of the U.S. market. This broad coverage removes major friction points for prescription fills and ensures high revenue realization per active patient.
🐻 Bear Case
New patient start forms have decelerated sharply for two consecutive quarters (646 -> 397 -> 207). If this trend continues, sequential revenue growth will stall or reverse in the second half of 2026.
Despite 207 new start forms in Q4, net active patients only grew by 95 (from 764 to 859). This implies either a rising discontinuation rate among early cohorts or severe delays in converting forms to paid scripts.
⚖️ Verdict: ⚪
Cautiously Optimistic. The current financial execution is flawless, and the cash generation provides a massive safety net. However, the steep drop in patient start forms cannot be ignored and must stabilize soon to justify long-term growth expectations.
Key Themes
Patient Start Forms Contradict Management Narrative
CEO Anish Bhatnagar cited the 'positive trajectory of our other leading indicators, including patient start forms.' The data explicitly contradicts this. Start forms are decelerating rapidly: 646 in Q2, 397 in Q3, and 207 in Q4. While Q2 benefited from pent-up demand, the continued drop from Q3 to Q4 suggests the core addressable market is being exhausted faster than anticipated or that physicians are hesitating. This is a major red flag for forward-looking growth.
Payer Coverage Expanding Rapidly
Market access is accelerating. Lives covered jumped from 100M in Q2, to 132M in Q3, to 185M by the end of Q4. This structural driver ensures that when start forms are submitted, they have a high probability of converting to paid commercial scripts without prolonged appeals processes. It signifies strong validation of VYKAT XR's clinical utility by major U.S. insurers.
High Implied Discontinuation or Conversion Friction
In Q4, Soleno received 207 start forms, yet the active patient count only increased by 95 (from 764 in Q3 to 859 in Q4). This leaves 112 patients unaccounted for. Either the conversion timeline from start form to active script has elongated significantly, or the discontinuation rate of the Q2/Q3 cohorts is spiking. Management noted in Q3 that discontinuations were around 10% (partly due to a short-seller report); the math suggests this rate may have climbed.
First-Mover Monopoly in a Severe Disease
VYKAT XR remains the first and only FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS). This technological monopoly allows Soleno to dictate pricing and command deep penetration within Centers of Excellence. With zero direct approved competitors, Soleno captures 100% of the treated market.
Macro Seasonality and External Headwinds
Management previously attributed Q3's start form slowdown to macroeconomic seasonality (summer holidays) and a short-seller report. The continued slump in Q4 suggests either the seasonal holiday effect (Thanksgiving/Christmas) is unusually severe for this patient population, or the reputational damage from the short report regarding non-serious adverse events has lingered, causing sustained hesitancy among community prescribers.
European Expansion Offers Next Leg of Growth
With the U.S. launch maturing, international markets represent the next major catalyst. Soleno submitted its Marketing Authorization Application (MAA) to the EMA in Q2 and responded to Day 120 questions. The EU4 and U.K. represent an estimated 9,500 patients. Approval in this territory would nearly double the company's total addressable market.
Artificially High Gross Margins Will Compress
Q4 Cost of Goods Sold (COGS) was a minuscule $0.86M on $91.7M in revenue (99.1% gross margin). As noted by the CFO in prior quarters, this is artificially boosted by zero-cost inventory manufactured prior to FDA approval. As this legacy inventory is depleted in FY26, COGS will normalize, leading to a deceleration in gross margin percentage.
Other KPIs
Reversing the cash burn trajectory of early 2025, operating cash flow accelerated from $43.5M in Q3 to $48.7M in Q4. This phenomenal cash conversion proves the underlying business model is highly lucrative once the commercial infrastructure is in place.
Down slightly from $556.1M in Q3, but this includes the execution of a $100M Accelerated Share Repurchase (ASR) program in Q4. The fact that Soleno could absorb a $100M buyback and still end with over half a billion in liquidity highlights immense balance sheet strength.
Accelerating from $33.8M in Q3. Included $8.7M in non-cash stock-based compensation. The cash portion of SG&A is increasing logically as the company scales its commercial field force and disease state education programs, but it remains well outpaced by revenue growth.
Guidance
Management explicitly guided that SG&A expenses will continue to rise as the company pushes further into the commercialization of VYKAT XR and prepares for potential European expansion. No specific dollar range was provided.
R&D will be driven by the initiation of new evaluations for DCCR (diazoxide choline) in additional high-need rare diseases, marking a pivot from purely regulatory support for PWS toward pipeline expansion.
Key Questions
Start Form Deceleration
Start forms dropped sequentially from 646 to 397 to 207. Why is management characterizing this as a 'positive trajectory', and what is the normalized, steady-state expectation for quarterly start forms going forward?
Implied Discontinuation Rate
With 207 new start forms but only 95 net active patients added in Q4, the math implies a significant bottleneck or drop-off. Has the discontinuation rate increased beyond the ~10% mentioned in Q3, or is this a delay in specialty pharmacy fulfillment?
Gross Margin Normalization
At what specific point in FY26 will the zero-cost pre-approval inventory be fully depleted, and what is the expected normalized gross margin profile once you are selling fully-costed drug?